Haploidentical Hematopoietic Stem Cell Transplantation With Ex Vivo TCR Alpha/Beta and CD19 Depletion in Pediatric Hematologic Malignancies

Inclusion Criteria

• •Must meet at least one of the following disease criteria:
• •* B cell ALL in first remission and any of the following:
• •* Persistent flow-based MRD at end-of-consolidation:
• •* ≥ 1% for NCI SR ALL
• •* ≥ 0.01% for NCI HR ALL
• •* TCF3-HLF t(17;19)
• •* KMT2A rearranged infant ALL, \< 6 months of age and presenting WBC of \> 300,000 or poor steroid response (peripheral blasts \>= 1000 /uL on day 8 of therapy
• •* Other high-risk features not explicitly stated here, after discussion/approval with protocol PI.
• •* B cell ALL in second remission and any of the following:
• •* Early (\<36 months from start of therapy) marrow or combined relapse
• +62 more criteria